Eli Lilly在2025年的成功是由糖尿病和减重药物驱动的, 加上重要的药物进步和主要的人工智能投资。 Eli Lilly's 2025 success driven by diabetes and weight-loss drugs, with key drug advances and major AI investments.

礼来公司在2025年公布了强劲业绩，这得益于其糖尿病和减肥药物，尤其是tirzepatide的高需求。 Eli Lilly posted strong 2025 results fueled by high demand for its diabetes and weight-loss drugs, especially tirzepatide. 公司取得了广泛的临床成功,其新一代肥胖药物雷塔,口服GLP-1或forglipron,癌症药物Jaypirca和阿尔茨海默症治疗药物Kisunla的第三期试验结果呈阳性,该药物显示有潜力减缓认知衰退. The company achieved broad clinical success, with positive phase 3 results for its next-gen obesity drug retatrutide, oral GLP-1 orforglipron, cancer drug Jaypirca, and Alzheimer’s treatment Kisunla, which showed potential to slow cognitive decline. 它正在对AI进行大量投资,包括建造一家主要的AI超级计算机,以加速药物发现。 It is investing heavily in AI, including building a major AI supercomputer, to accelerate drug discovery. 这些进步,加上可靠的财务和股东回报,突出显示了其除新陈代谢疾病以外的日益扩大的影响。 These advances, along with solid financials and shareholder returns, underscore its growing influence beyond metabolic diseases.